242 related articles for article (PubMed ID: 35456895)
1. In Situ PD-L1 Expression in Oral Squamous Cell Carcinoma Is Induced by Heterogeneous Mechanisms among Patients.
Kondo Y; Suzuki S; Ono S; Goto M; Miyabe S; Ogawa T; Tsuchida H; Ito H; Takahara T; Satou A; Tsuzuki T; Yoshikawa K; Ueda R; Nagao T
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35456895
[TBL] [Abstract][Full Text] [Related]
2. Triptolide suppresses oral cancer cell PD-L1 expression in the interferon-γ-modulated microenvironment in vitro, in vivo, and in clinical patients.
Kuo CS; Yang CY; Lin CK; Lin GJ; Sytwu HK; Chen YW
Biomed Pharmacother; 2021 Jan; 133():111057. PubMed ID: 33378962
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor induces STAT1 expression to exacerbate the IFNr-mediated PD-L1 axis in epidermal growth factor receptor-positive cancers.
Cheng CC; Lin HC; Tsai KJ; Chiang YW; Lim KH; Chen CG; Su YW; Peng CL; Ho AS; Huang L; Chang YC; Lin HC; Chang J; Chang YF
Mol Carcinog; 2018 Nov; 57(11):1588-1598. PubMed ID: 30035369
[TBL] [Abstract][Full Text] [Related]
4. The involvement of epidermal growth factor receptor/protein kinase B signaling in the tumor intrinsic PD-L1-induced malignant potential of oral squamous cell carcinoma.
Sasabe E; Tomomura A; Yamamoto T
J Oral Pathol Med; 2024 May; 53(5):310-320. PubMed ID: 38693616
[TBL] [Abstract][Full Text] [Related]
5. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
6. TLR9 activation induces immunosuppression and tumorigenesis via PARP1/PD-L1 signaling pathway in oral squamous cell carcinoma.
Ma L; Qin N; Wan W; Song S; Hua S; Jiang C; Li N; Huang L; Gao X
Am J Physiol Cell Physiol; 2024 Feb; 326(2):C362-C381. PubMed ID: 38105756
[TBL] [Abstract][Full Text] [Related]
7. miR-375 inhibits IFN-γ-induced programmed death 1 ligand 1 surface expression in head and neck squamous cell carcinoma cells by blocking JAK2/STAT1 signaling.
Wu Q; Zhao Y; Sun Y; Yan X; Wang P
Oncol Rep; 2018 Mar; 39(3):1461-1468. PubMed ID: 29328389
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia-inducible factor-1α and nuclear factor-κB play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non-small-cell lung cancer cells.
Guo R; Li Y; Wang Z; Bai H; Duan J; Wang S; Wang L; Wang J
Cancer Sci; 2019 May; 110(5):1665-1675. PubMed ID: 30844110
[TBL] [Abstract][Full Text] [Related]
9. IL-33/ST2 signaling promotes constitutive and inductive PD-L1 expression and immune escape in oral squamous cell carcinoma.
Zhao M; He Y; Zhu N; Song Y; Hu Q; Wang Z; Ni Y; Ding L
Br J Cancer; 2023 Mar; 128(5):833-843. PubMed ID: 36463324
[TBL] [Abstract][Full Text] [Related]
10. Differential expression of programmed death-1 and its ligand, programmed death ligand-1 in oral squamous cell carcinoma with and without oral submucous fibrosis.
Quan H; Liu S; Shan Z; Liu Z; Chen T; Hu Y; Yao Z; Fang L
Arch Oral Biol; 2020 Nov; 119():104916. PubMed ID: 32977151
[TBL] [Abstract][Full Text] [Related]
11. Programmed death-ligand 1 is prognostic factor in esophageal squamous cell carcinoma and is associated with epidermal growth factor receptor.
Zhang W; Pang Q; Zhang X; Yan C; Wang Q; Yang J; Yu S; Liu X; Pan Y; Yuan Z; Wang P; Xiao Z
Cancer Sci; 2017 Apr; 108(4):590-597. PubMed ID: 28192623
[TBL] [Abstract][Full Text] [Related]
12. IFN-γ-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling.
Gao Y; Yang J; Cai Y; Fu S; Zhang N; Fu X; Li L
Int J Cancer; 2018 Aug; 143(4):931-943. PubMed ID: 29516506
[TBL] [Abstract][Full Text] [Related]
13. mRNA expression of programmed cell death ligand 1 and components of the phosphatidylinositol 3-kinase/AKT/phosphatase and tensin homolog pathway in epidermal growth factor receptor mutation-positive lung adenocarcinoma.
Han K; Zhang Y
J Cancer Res Ther; 2019; 15(4):914-920. PubMed ID: 31436252
[TBL] [Abstract][Full Text] [Related]
14. PKD3 promotes metastasis and growth of oral squamous cell carcinoma through positive feedback regulation with PD-L1 and activation of ERK-STAT1/3-EMT signalling.
Cui B; Chen J; Luo M; Liu Y; Chen H; Lü D; Wang L; Kang Y; Feng Y; Huang L; Zhang P
Int J Oral Sci; 2021 Mar; 13(1):8. PubMed ID: 33692335
[TBL] [Abstract][Full Text] [Related]
15. Identification of a Favorable Prognostic Subgroup in Oral Squamous Cell Carcinoma: Characterization of ITGB4/PD-L1
Ma SR; Liu JF; Jia R; Deng WW; Jia J
Biomolecules; 2023 Jun; 13(6):. PubMed ID: 37371594
[TBL] [Abstract][Full Text] [Related]
16. Triptolide reduces PD-L1 through the EGFR and IFN-γ/IRF1 dual signaling pathways.
Xie Y; Ding J; Gao J; Zhang J; Cen S; Zhou J
Int Immunopharmacol; 2023 May; 118():109993. PubMed ID: 36931170
[TBL] [Abstract][Full Text] [Related]
17. AIM2 promotes irradiation resistance, migration ability and PD-L1 expression through STAT1/NF-κB activation in oral squamous cell carcinoma.
Chiu HW; Lee HL; Lee HH; Lu HW; Lin KY; Lin YF; Lin CH
J Transl Med; 2024 Jan; 22(1):13. PubMed ID: 38166970
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of epidermal growth factor receptor and programmed cell death-ligand 1 co-expression in esophageal squamous cell carcinoma.
Jiang G; Miao Y; Wang Z; Zhang Q; Zhou P; Zhang F
Aging (Albany NY); 2023 Feb; 15(4):1107-1129. PubMed ID: 36812484
[TBL] [Abstract][Full Text] [Related]
19. CD274/PD-L1 gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity.
Straub M; Drecoll E; Pfarr N; Weichert W; Langer R; Hapfelmeier A; Götz C; Wolff KD; Kolk A; Specht K
Oncotarget; 2016 Mar; 7(11):12024-34. PubMed ID: 26918453
[TBL] [Abstract][Full Text] [Related]
20. PER2 binding to HSP90 enhances immune response against oral squamous cell carcinoma by inhibiting IKK/NF-κB pathway and PD-L1 expression.
Zhang Z; Sun D; Tang H; Ren J; Yin S; Yang K
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37914384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]